Pava Partners advised Genedata AG on its sale to Danaher Corporation, enhancing Danaher's offerings in the biopharmaceutical software solutions sector.

Target Information

Pava Partners advised the shareholders of Genedata AG, a leading provider of software solutions for biopharmaceutical research and development, on its sale to Danaher Corporation (NYSE: DHR), a global leader in Life Sciences and Diagnostics. Established in 1997 and headquartered in Basel, Switzerland, Genedata excels in transforming data into actionable insights for the life sciences sector. The company offers scalable and open solutions that enhance productivity in research and development, thereby serving major biopharmaceutical firms and innovative biotechnology companies worldwide. Prior to this transaction, Genedata and Danaher had established several successful collaborations, underscoring their complementary strengths.

Genedata's innovative approach focuses on digitizing research and development processes to expedite the delivery of life-saving and personalized medicines. According to Othmar Pfannes, Ph.D., founder and CEO of Genedata, the company’s success is grounded in the dedication and expertise of its teams, which have earned the trust of clients across the globe. As part of the Danaher Group, Genedata aims to continue attracting top talent and solving complex challenges for its customers worldwide.

Industry Overview

The biopharmaceutical industry in Switzerland is renowned for its strong emphasis on research and innovation, bolstered by a robust ecosystem of leading universities and research institutions. Switzerland’s strategic location in Europe enables efficient